Skip Navigation

FDA Issues Guidance For Clinical Research Using Cannabis

CITI Program 24 July 2020 by CITI Program

The FDA has issued guidance detailing the FDA’s current thinking on clinical research with cannabis and cannabis-derived compounds. It includes quality considerations, reviews key FDA regulatory concepts, and provides recommendations related to cannabis sources and THC percentage calculation. See the full guidance for more details:

Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research


CITI Program’s Medical Marijuana Webinar

This webinar discusses medical marijuana and related cannabis products, unique challenges and issues for research, and the application of the Common Rule and the Belmont Report’s ethical framework to this research. It also covers practical issues for researchers, IRBs, and institutional administrators.
View Webinar Details